WO2007128802A3 - Use of flibanserin for the treatment of post-menopausal sexual desire disorders - Google Patents

Use of flibanserin for the treatment of post-menopausal sexual desire disorders Download PDF

Info

Publication number
WO2007128802A3
WO2007128802A3 PCT/EP2007/054380 EP2007054380W WO2007128802A3 WO 2007128802 A3 WO2007128802 A3 WO 2007128802A3 EP 2007054380 W EP2007054380 W EP 2007054380W WO 2007128802 A3 WO2007128802 A3 WO 2007128802A3
Authority
WO
WIPO (PCT)
Prior art keywords
flibanserin
post
treatment
sexual desire
desire disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2007/054380
Other languages
French (fr)
Other versions
WO2007128802A2 (en
Inventor
Stephane Pollentier
Robert Pyke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Boehringer Ingelheim Pharma GmbH and Co KG
Boehringer Ingelheim Pharmaceuticals Inc
Original Assignee
Boehringer Ingelheim International GmbH
Boehringer Ingelheim Pharma GmbH and Co KG
Boehringer Ingelheim Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38566195&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2007128802(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to PL07728833T priority Critical patent/PL2021006T3/en
Priority to RS20150713A priority patent/RS54398B1/en
Priority to JP2009508365A priority patent/JP2009536176A/en
Priority to MX2008013827A priority patent/MX2008013827A/en
Priority to UAA200813663A priority patent/UA97950C2/en
Priority to EP07728833.0A priority patent/EP2021006B1/en
Priority to DK07728833.0T priority patent/DK2021006T3/en
Priority to SI200731692T priority patent/SI2021006T1/en
Priority to NZ573382A priority patent/NZ573382A/en
Application filed by Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH and Co KG, Boehringer Ingelheim Pharmaceuticals Inc filed Critical Boehringer Ingelheim International GmbH
Priority to CA002649938A priority patent/CA2649938A1/en
Priority to EA200802208A priority patent/EA200802208A1/en
Priority to ES07728833.0T priority patent/ES2551093T3/en
Priority to BRPI0712039-7A priority patent/BRPI0712039A2/en
Priority to AU2007247094A priority patent/AU2007247094B2/en
Publication of WO2007128802A2 publication Critical patent/WO2007128802A2/en
Publication of WO2007128802A3 publication Critical patent/WO2007128802A3/en
Priority to NO20084531A priority patent/NO20084531L/en
Priority to IL195135A priority patent/IL195135A0/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The invention relates to the use of flibanserin for the preparation of a medicament for the treatment of post-menopausal Sexual Desire Disorders.
PCT/EP2007/054380 2006-05-09 2007-05-07 Use of flibanserin for the treatment of post-menopausal sexual desire disorders Ceased WO2007128802A2 (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
AU2007247094A AU2007247094B2 (en) 2006-05-09 2007-05-07 Use of flibanserin for the treatment of post-menopausal Sexual Desire Disorders
CA002649938A CA2649938A1 (en) 2006-05-09 2007-05-07 Use of flibanserin for the treatment of post-menopausal sexual desire disorders
JP2009508365A JP2009536176A (en) 2006-05-09 2007-05-07 Use of flibanserin for the treatment of postmenopausal sexual desire disorders
MX2008013827A MX2008013827A (en) 2006-05-09 2007-05-07 Use of flibanserin for the treatment of post-menopausal sexual desire disorders.
UAA200813663A UA97950C2 (en) 2006-05-09 2007-05-07 Use of flibanserin for the treatment of post-menopausal sexual desire disorders
EP07728833.0A EP2021006B1 (en) 2006-05-09 2007-05-07 Use of flibanserin for the treatment of post-menopausal sexual desire disorders
DK07728833.0T DK2021006T3 (en) 2006-05-09 2007-05-07 USE OF flibanserin in postmenopausal SEXLYSTFORSTYRRELSER
SI200731692T SI2021006T1 (en) 2006-05-09 2007-05-07 Use of flibanserin for the treatment of post-menopausal sexual desire disorders
NZ573382A NZ573382A (en) 2006-05-09 2007-05-07 Use of flibanserin for the treatment of post-menopausal sexual desire disorders
PL07728833T PL2021006T3 (en) 2006-05-09 2007-05-07 Use of flibanserin for the treatment of post-menopausal sexual desire disorders
ES07728833.0T ES2551093T3 (en) 2006-05-09 2007-05-07 Use of flibanserin for the treatment of sexual desire disorders after menopause
RS20150713A RS54398B1 (en) 2006-05-09 2007-05-07 THE USE OF FLIBANSERINE FOR THE TREATMENT OF SEXUAL DESIRE DISORDERS IN POSTMENOPAUSE
EA200802208A EA200802208A1 (en) 2006-05-09 2007-05-07 APPLICATION OF FLIBANSTERIN FOR THE TREATMENT OF DISEASES OF THE SEXUAL TREATMENT IN THE POST-CLIMACTERNIC PERIOD
BRPI0712039-7A BRPI0712039A2 (en) 2006-05-09 2007-05-07 use of flibanserin for the treatment of postmenopausal sexual desire disorders
NO20084531A NO20084531L (en) 2006-05-09 2008-10-28 Use of flibanserin for the treatment of post-menopausal sexual desire disorders
IL195135A IL195135A0 (en) 2006-05-09 2008-11-06 Use of flibanserin for the treatment of post-menopausal sexual desire disorders

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US74681706P 2006-05-09 2006-05-09
US60/746,817 2006-05-09
US83098706P 2006-07-14 2006-07-14
US60/830,987 2006-07-14

Publications (2)

Publication Number Publication Date
WO2007128802A2 WO2007128802A2 (en) 2007-11-15
WO2007128802A3 true WO2007128802A3 (en) 2008-06-12

Family

ID=38566195

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/054380 Ceased WO2007128802A2 (en) 2006-05-09 2007-05-07 Use of flibanserin for the treatment of post-menopausal sexual desire disorders

Country Status (27)

Country Link
US (4) US20070265276A1 (en)
EP (1) EP2021006B1 (en)
JP (1) JP2009536176A (en)
KR (1) KR20090005371A (en)
AR (1) AR060880A1 (en)
AU (1) AU2007247094B2 (en)
BR (1) BRPI0712039A2 (en)
CA (1) CA2649938A1 (en)
CL (1) CL2007001318A1 (en)
DK (1) DK2021006T3 (en)
EA (1) EA200802208A1 (en)
EC (1) ECSP088874A (en)
ES (1) ES2551093T3 (en)
HU (1) HUE026156T2 (en)
IL (1) IL195135A0 (en)
MX (1) MX2008013827A (en)
MY (1) MY151048A (en)
NO (1) NO20084531L (en)
NZ (1) NZ573382A (en)
PE (1) PE20080090A1 (en)
PL (1) PL2021006T3 (en)
PT (1) PT2021006E (en)
RS (1) RS54398B1 (en)
SI (1) SI2021006T1 (en)
TW (1) TW200812586A (en)
UY (1) UY30333A1 (en)
WO (1) WO2007128802A2 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7183410B2 (en) * 2001-08-02 2007-02-27 Bidachem S.P.A. Stable polymorph of flibanserin
US20030060475A1 (en) * 2001-08-10 2003-03-27 Boehringer Ingelheim Pharma Kg Method of using flibanserin for neuroprotection
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
UA78974C2 (en) * 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US20040048877A1 (en) * 2002-05-22 2004-03-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions containing flibanserin
US20050239798A1 (en) * 2004-04-22 2005-10-27 Boehringer Ingelheim Pharmaceuticals, Inc. Method for the treatment of premenstrual and other female sexual disorders
WO2006096439A2 (en) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
JP2008531714A (en) * 2005-03-04 2008-08-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Pharmaceutical composition for the treatment and / or prevention of anxiety disorders
WO2006096435A1 (en) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of depression
WO2006119884A2 (en) * 2005-05-06 2006-11-16 Boehringer Ingelheim International Gmbh Method for the treatment of drug abuse with flibanserin
US20060264512A1 (en) * 2005-05-19 2006-11-23 Boehringer Ingelheim International Gmbh Method for the treatment of sexual dysfunction due to medical conditions
JP2008540673A (en) * 2005-05-19 2008-11-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Method for treating drug-induced dysfunction
ES2646326T3 (en) 2005-08-03 2017-12-13 Sprout Pharmaceuticals, Inc. Use of flibanserin in the treatment of obesity
WO2007048803A1 (en) 2005-10-29 2007-05-03 Boehringer Ingelheim International Gmbh Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
WO2008000760A1 (en) 2006-06-30 2008-01-03 Boehringer Ingelheim International Gmbh Flibanserin for the treatment of urinary incontinence and related diseases
EP2043648A1 (en) * 2006-07-14 2009-04-08 Boehringer Ingelheim International GmbH Use of flibanserin for the treatment of sexual disorders in females
CL2007002214A1 (en) 2006-08-14 2008-03-07 Boehringer Ingelheim Int PHARMACEUTICAL COMPOSITION IN THE FORM OF COMPRESSED, WHERE AT LEAST THE LENGTH OF THE COMPRESSED IN THE PREVIOUS STATE OF THE APPLICATION IS AT LEAST 7/12 OF THE PILOR DIAMETER OF THE PATIENT AND AFTER INGERING IT IN THE FOOD STATE, THE LENGTH OF THE COMP
BRPI0716439B8 (en) 2006-08-14 2021-05-25 Boehringer Ingelheim Int pharmaceutical delivery systems comprising flibanserin, process for preparation and use thereof
BRPI0716436B8 (en) * 2006-08-25 2021-05-25 Boehringer Ingelheim Int controlled release system and method for manufacturing it
JP5087011B2 (en) * 2007-01-23 2012-11-28 馨 井上 Non-human animals for eye disease models
CL2008002693A1 (en) 2007-09-12 2009-10-16 Boehringer Ingelheim Int Use of flibanserin for the treatment of selected vasomotor symptoms of hot flashes, night sweats, mood swings, and irritability
USD915009S1 (en) 2018-08-16 2021-03-30 Samsung Electronics Co., Ltd. Clothing care machine
USD1017150S1 (en) 2021-12-28 2024-03-05 Samsung Electronics Co., Ltd. Clothing care machine

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003035072A1 (en) * 2001-10-20 2003-05-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of flibanserin in the treatment of sexual disorders
WO2005007166A1 (en) * 2003-07-16 2005-01-27 Pfizer Limited Treatment of sexual dysfunction
WO2005102343A1 (en) * 2004-04-22 2005-11-03 Boehringer Ingelheim Pharmaceuticals, Inc. Use of flibanserin in the treatment of premenstrual and other female sexual disorders

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3096248A (en) * 1959-04-06 1963-07-02 Rexall Drug & Chemical Company Method of making an encapsulated tablet
US3406178A (en) * 1964-02-04 1968-10-15 Monsanto Chem Australia Ltd Preparation of 2-substituted benzimidazoles
US3362956A (en) * 1965-08-19 1968-01-09 Sterling Drug Inc 1-[(heterocyclyl)-lower-alkyl]-4-substituted-piperazines
US4200641A (en) * 1976-12-21 1980-04-29 Janssen Pharmaceutica, N.V. 1-[(Heterocyclyl)-alkyl]-4-diarylmethoxy piperidine derivatives
DE3000979A1 (en) * 1980-01-12 1981-07-23 Dr. Karl Thomae Gmbh, 7950 Biberach NEW DIPYRIDAMOL RETARD FORMS AND METHOD FOR THEIR PRODUCTION
IT1176613B (en) * 1984-08-14 1987-08-18 Ravizza Spa PHARMACOLOGICALLY ACTIVE PIPERAZINIC DERIVATIVES AND PROCESS FOR THEIR PREPARATION
GB8607294D0 (en) * 1985-04-17 1986-04-30 Ici America Inc Heterocyclic amide derivatives
NL8601494A (en) * 1985-06-22 1987-01-16 Sandoz Ag THIAZOLS, THEIR PREPARATIONS AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM.
GB8601160D0 (en) * 1986-01-17 1986-02-19 Fujisawa Pharmaceutical Co Heterocyclic compounds
US5036088A (en) * 1986-06-09 1991-07-30 Pfizer Inc. Antiallergy and antiinflammatory agents, compositions and use
JPH0784462B2 (en) * 1986-07-25 1995-09-13 日清製粉株式会社 Benzimidazole derivative
US4792452A (en) * 1987-07-28 1988-12-20 E. R. Squibb & Sons, Inc. Controlled release formulation
GB8830312D0 (en) * 1988-12-28 1989-02-22 Lundbeck & Co As H Heterocyclic compounds
US4954503A (en) * 1989-09-11 1990-09-04 Hoechst-Roussel Pharmaceuticals, Inc. 3-(1-substituted-4-piperazinyl)-1H-indazoles
NZ241613A (en) * 1991-02-27 1993-06-25 Janssen Pharmaceutica Nv Highlighting intagliations in tablets
SE9100860D0 (en) * 1991-03-22 1991-03-22 Kabi Pharmacia Ab NEW USE
IT1251144B (en) * 1991-07-30 1995-05-04 Boehringer Ingelheim Italia BENZIMIDAZOLONE DERIVATIVES
US5407686A (en) * 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5225417A (en) * 1992-01-21 1993-07-06 G. D. Searle & Co. Opioid agonist compounds
US5492907A (en) * 1992-12-09 1996-02-20 The United States Of America As Represented By The Department Of Health & Human Services Antipsychotic composition and method of treatment
FR2707294B1 (en) * 1993-07-06 1995-09-29 Pf Medicament New derivatives of 3,5-dioxo- (2H, 4H) -1,2,4-triazine, their preparation and their application in human therapy.
CA2179383A1 (en) * 1994-01-14 1995-07-20 Ira D. Goldfine Antagonists to insulin receptor tyrosine kinase inhibitor
FR2727682A1 (en) * 1994-12-02 1996-06-07 Pf Medicament NOVEL DERIVATIVES OF 3,5-DIOXO- (2H, 4H) -1,2,4-TRIAZINES, THEIR PREPARATION AND THEIR USE AS A MEDICINAL PRODUCT
US5552412A (en) * 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
US5883094A (en) * 1995-04-24 1999-03-16 Pfizer Inc. Benzimidazolone derivatives with central dopaminergic activity
US5854290A (en) * 1995-09-21 1998-12-29 Amy F. T. Arnsten Use of guanfacine in the treatment of behavioral disorders
US6083947A (en) * 1996-01-29 2000-07-04 The Regents Of The University Of California Method for treating sexual dysfunctions
US5916916A (en) * 1996-10-10 1999-06-29 Eli Lilly And Company 1-aryloxy-2-arylnaphthyl compounds, intermediates, compositions, and methods
AU731349B2 (en) * 1996-12-02 2001-03-29 Merck Sharp & Dohme Limited Use of NK-1 receptor antagonists for treating sexual dysfunctions
PL337813A1 (en) * 1997-06-11 2000-09-11 Procter & Gamble Coated tablet with a coating ensuring safe administration for upper portion of the gastrointestinal tract
DE69815003T2 (en) * 1997-09-10 2004-04-01 Takeda Chemical Industries, Ltd. Stabilized pharmaceutical composition
CH692199A8 (en) * 1997-10-09 2002-06-14 Cermol S.A. PYRIDIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS
JP3724157B2 (en) * 1997-10-30 2005-12-07 コニカミノルタホールディングス株式会社 Video observation device
FR2775188B1 (en) * 1998-02-23 2001-03-09 Lipha IMMEDIATE RELEASE ORAL EXTENDED RELEASE GALENIC FORM COMPRISING AN ABSORPTION PROMOTING AGENT AND USE OF THE ABSORPTION PROMOTING AGENT
US20020151543A1 (en) * 1998-05-28 2002-10-17 Sepracor Inc. Compositions and methods employing R (-) fluoxetine and other active ingredients
US6068846A (en) * 1998-08-05 2000-05-30 Melaleuca, Incorporated Methods and materials for treating depression and mood disorder
EP0982030A3 (en) * 1998-08-17 2000-05-10 Pfizer Products Inc. 2,7-substituted octahydro-pyrrolo 1,2-a]pyrazine derivatives as 5ht 1a ligands
US6680071B1 (en) * 1999-03-03 2004-01-20 R. P. Scherer Technologies, Inc. Opioid agonist in a fast dispersing dosage form
US6346548B1 (en) * 1999-08-16 2002-02-12 Cephalon, Inc. Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue
IT1313625B1 (en) * 1999-09-22 2002-09-09 Boehringer Ingelheim Italia BENZIMIDAZOLONIC DERIVATIVES WITH MIXED AFFINITY FOR DYEROTONIN AND DOPAMIN RECEPTORS.
PT1257277E (en) * 2000-02-24 2005-09-30 Pharmacia & Upjohn Co Llc NEW DRUG COMBINATIONS
US6521623B1 (en) * 2000-09-19 2003-02-18 Boehringer Ingelheim Pharma Kg N,N'-disubstituted benzimidazolone derivatives with affinity at the serotonin and dopamine receptors
US6586435B2 (en) * 2000-09-19 2003-07-01 Boehringer Ingelheim Pharma Kg Benzimidazolone derivatives displaying affinity at the serotonin and dopamine receptors
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
US7183410B2 (en) * 2001-08-02 2007-02-27 Bidachem S.P.A. Stable polymorph of flibanserin
PT1414816E (en) * 2001-08-02 2005-04-29 Bidachem Spa FLIBANSERIN STABILIZABLE POLYMORPHINE, TECHNICAL PROCESS FOR PREPARING AND USING THE PREPARATION OF MEDICINES
US20030060475A1 (en) * 2001-08-10 2003-03-27 Boehringer Ingelheim Pharma Kg Method of using flibanserin for neuroprotection
DE10149674A1 (en) * 2001-10-09 2003-04-24 Apogepha Arzneimittel Gmbh Orally administered composition for sustained release of propiverine, useful for treatment of hypertonic bladder disorders, especially by once-daily administration
DE10209982A1 (en) * 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Dosage form to be administered orally for poorly soluble basic active ingredients
US20040048877A1 (en) * 2002-05-22 2004-03-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions containing flibanserin
US20040132697A1 (en) * 2002-11-06 2004-07-08 Pfizer Inc. Treatment of female sexual dysfunction
WO2004063864A2 (en) * 2003-01-06 2004-07-29 Laura Berman Method and system for computerized sexual function assessment of female users
CA2563743A1 (en) * 2004-04-22 2005-11-03 Boehringer Ingelheim International Gmbh New pharmaceutical compositions for the treatment of sexual disorders ii
US20060014757A1 (en) * 2004-07-14 2006-01-19 Boehringer Ingelheim Pharmaceuticals Method for the treatment of anorexia nervosa
US20060025420A1 (en) * 2004-07-30 2006-02-02 Boehringer Ingelheimn International GmbH Pharmaceutical compositions for the treatment of female sexual disorders
WO2006024471A1 (en) * 2004-09-03 2006-03-09 Boehringer Ingelheim International Gmbh Method for the treatment of attention deficit hyperactivity disorder
JP2008531714A (en) * 2005-03-04 2008-08-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Pharmaceutical composition for the treatment and / or prevention of anxiety disorders
WO2006096435A1 (en) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of depression
WO2006096439A2 (en) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
WO2006119884A2 (en) * 2005-05-06 2006-11-16 Boehringer Ingelheim International Gmbh Method for the treatment of drug abuse with flibanserin
US20060258640A1 (en) * 2005-05-13 2006-11-16 Boehringer Ingelheim International Gmbh Use of Flibanserin in the treatment of chronic pain
JP2008540673A (en) * 2005-05-19 2008-11-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Method for treating drug-induced dysfunction
US20060264512A1 (en) * 2005-05-19 2006-11-23 Boehringer Ingelheim International Gmbh Method for the treatment of sexual dysfunction due to medical conditions
ES2646326T3 (en) * 2005-08-03 2017-12-13 Sprout Pharmaceuticals, Inc. Use of flibanserin in the treatment of obesity
US20070123540A1 (en) * 2005-10-29 2007-05-31 Angelo Ceci Sexual desire enhancing medicaments comprising benzimidazolone derivatives
WO2007048803A1 (en) * 2005-10-29 2007-05-03 Boehringer Ingelheim International Gmbh Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
US20070105869A1 (en) * 2005-11-08 2007-05-10 Stephane Pollentier Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
CA2641917A1 (en) * 2006-02-18 2007-08-23 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment of attention deficit hyperactivity disorder comprising flibanserin
CA2642101A1 (en) * 2006-02-20 2007-08-30 Boehringer Ingelheim International Gmbh Benzimidazolone derivatives for the treatment of urinary incontinence
EP1991228A1 (en) * 2006-02-28 2008-11-19 Boehringer Ingelheim International GmbH Treatment of prevention of valvular heart disease with flibanserin
WO2008000760A1 (en) * 2006-06-30 2008-01-03 Boehringer Ingelheim International Gmbh Flibanserin for the treatment of urinary incontinence and related diseases
JP2009543767A (en) * 2006-07-14 2009-12-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Composition comprising flibanserin and caffeine, its preparation method and use as a medicine
EP2043648A1 (en) * 2006-07-14 2009-04-08 Boehringer Ingelheim International GmbH Use of flibanserin for the treatment of sexual disorders in females
BRPI0716439B8 (en) * 2006-08-14 2021-05-25 Boehringer Ingelheim Int pharmaceutical delivery systems comprising flibanserin, process for preparation and use thereof
CL2007002214A1 (en) * 2006-08-14 2008-03-07 Boehringer Ingelheim Int PHARMACEUTICAL COMPOSITION IN THE FORM OF COMPRESSED, WHERE AT LEAST THE LENGTH OF THE COMPRESSED IN THE PREVIOUS STATE OF THE APPLICATION IS AT LEAST 7/12 OF THE PILOR DIAMETER OF THE PATIENT AND AFTER INGERING IT IN THE FOOD STATE, THE LENGTH OF THE COMP
BRPI0716436B8 (en) * 2006-08-25 2021-05-25 Boehringer Ingelheim Int controlled release system and method for manufacturing it

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003035072A1 (en) * 2001-10-20 2003-05-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of flibanserin in the treatment of sexual disorders
WO2005007166A1 (en) * 2003-07-16 2005-01-27 Pfizer Limited Treatment of sexual dysfunction
WO2005102343A1 (en) * 2004-04-22 2005-11-03 Boehringer Ingelheim Pharmaceuticals, Inc. Use of flibanserin in the treatment of premenstrual and other female sexual disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FOURCROY J L: "Female sexual dysfunction: Potential for pharmacotherapy", DRUGS, ADIS INTERNATIONAL LTD, AT, vol. 63, no. 14, 2003, pages 1445 - 1457, XP009050771, ISSN: 0012-6667 *

Also Published As

Publication number Publication date
US20150051221A1 (en) 2015-02-19
UY30333A1 (en) 2008-01-02
MY151048A (en) 2014-03-31
AR060880A1 (en) 2008-07-16
BRPI0712039A2 (en) 2011-12-20
EP2021006A2 (en) 2009-02-11
MX2008013827A (en) 2008-11-10
AU2007247094B2 (en) 2012-11-01
US20070265276A1 (en) 2007-11-15
SI2021006T1 (en) 2016-01-29
PL2021006T3 (en) 2015-12-31
EP2021006B1 (en) 2015-08-12
HUE026156T2 (en) 2016-06-28
AU2007247094A1 (en) 2007-11-15
KR20090005371A (en) 2009-01-13
US20130190326A1 (en) 2013-07-25
RS54398B1 (en) 2016-04-28
US20150374683A1 (en) 2015-12-31
CL2007001318A1 (en) 2008-01-18
NO20084531L (en) 2008-12-02
TW200812586A (en) 2008-03-16
DK2021006T3 (en) 2015-11-23
IL195135A0 (en) 2009-09-22
ECSP088874A (en) 2008-12-30
CA2649938A1 (en) 2007-11-15
PT2021006E (en) 2015-11-12
NZ573382A (en) 2012-02-24
PE20080090A1 (en) 2008-03-14
JP2009536176A (en) 2009-10-08
EA200802208A1 (en) 2009-04-28
WO2007128802A2 (en) 2007-11-15
ES2551093T3 (en) 2015-11-16

Similar Documents

Publication Publication Date Title
MY151048A (en) Use of flibanserin for the treatment of post-menopausal sexual desire disorders
MY145439A (en) Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
WO2007048801A3 (en) Sexual desire enhancing medicaments comprising benzimidazolone derivatives
WO2007025613A3 (en) Use of compounds binding to the sigma receptor for the treatment of diabetes-associated pain
IL178730A0 (en) New pharmaceutical compositions for the treatment of sexual disorders ii
EP2166837A4 (en) Drug combination for the treatment of skin disorders
SI2019683T1 (en) Administration of growth factors for the treatment of cns disorders
WO2008012555A3 (en) Epitope reduction therapy
WO2008095086A3 (en) Topiramate plus naltrexone for the treatment of addictive disorders
WO2008139263A3 (en) Methods for slowing the progression of multiple sclerosis
EP1976378A4 (en) Compounds for the treatment of metabolic disorders
IL193799A0 (en) New therapeutic combinations for the treatment or prevention of psycotic disorders
MX2010002032A (en) Treatment of vasomotor symptoms.
WO2010004031A3 (en) Treatment of amyotrophic lateral sclerosis by nogo-a-antagonist
WO2008094054A3 (en) 6, 8-dichlorchroman-3-yl-l, 3-dihydroimidazole-2-thione derivatives and their use for the treatment of cardiovascular disorders
WO2008051421A3 (en) Peptide-cytotoxic conjugates
GB0605376D0 (en) Preparation for the relief of disease
WO2009074498A8 (en) Medical use of 3- (2, 2, 2-trimethylhydrazinixm) propionate orotate
WO2007116297A3 (en) Use of aminapthone for the preparation of a medicament for treating arteriophaties
UA97950C2 (en) Use of flibanserin for the treatment of post-menopausal sexual desire disorders
UA96278C2 (en) Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
WO2008061966A3 (en) New use of flibanserin
WO2008028888A3 (en) Use of cripto-1 or cripto-3 for the treatment of skeletal muscle wasting
ZA200607463B (en) New pharmaceutical compositions for the treatment of sexual disorders II
WO2007084332A3 (en) Memantine for the normalization of visual acuity deficits

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07728833

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2007728833

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2008101689

Country of ref document: EG

WWE Wipo information: entry into national phase

Ref document number: 2649938

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/a/2008/013827

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 12008502448

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2009508365

Country of ref document: JP

Ref document number: 1020087027420

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 200780016960.5

Country of ref document: CN

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 9811/DELNP/2008

Country of ref document: IN

Ref document number: 200802208

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 573382

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2007247094

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: A200813663

Country of ref document: UA

ENP Entry into the national phase

Ref document number: 2007247094

Country of ref document: AU

Date of ref document: 20070507

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: PI0712039

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20081107

WWE Wipo information: entry into national phase

Ref document number: P-2015/0713

Country of ref document: RS